CTRI/2015/06/005944进行中（未招募）3 期
enalidomide plus low dose Dexamethasone versus Thalidmide plus low dose Dexamethasone for Multiple Myeloma: A Randomized Phase III study
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) Age 18 to 70 years
- •b) Adequate hemogram, liver, heart and kidney function
- •c) Performance status 0 to 2 (ECOG)
- •d) Two negative pregnancy tests (one before and the second 4 weeks after starting Thalidomide or Lenalidomide)
- •e) Willingness to participate in the study
排除标准
- •Hypersensitivity reaction to Thalidomide or Lenalidomide in the past
- •b) Pre-existing peripheral neuropathy more than grade 2
- •c) Uncontrolled diabetes mellitus
- •d) Renal failure
- •e) Significant ischemic cardiac disease eg LBBB
- •f) Uncontrolled psychiatric (depressive) disorder
研究者
相似试验
进行中（未招募）
不适用
enalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma.Multiple MyelomaEUCTR2015-001183-19-ESFundación PETHEMA306
进行中（未招募）
1 期
The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myelomaprimary treatment of multiple myeloma patients of age 60 till 75 yearsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2008-004083-39-DEGMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH348
招募中
不适用
ow dose of lenalidomide and dexamethasone therapy for eldery multiple myelomaRefractory or relapsed symptomatic multiple myelomaJPRN-UMIN000008918ishiwaki municipal hospital26
进行中（未招募）
不适用
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-ATWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure - LDThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-SKWilhelminen Krebsforschung GmbH50